Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can body awareness therapy stop delirium in stroke patients?

NCT ID NCT07249619

Prevention Sponsor: Emre Şenocak Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new approach to prevent delirium (sudden confusion) in patients with a type of stroke called subarachnoid hemorrhage who are in the intensive care unit. The program combines standard medical care with basic body awareness therapy and video-based communication. Researchers will compare this to routine care alone in 34 patients to see if it reduces delirium and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
biopsychosocial-based multimodal approach including basic body awareness therapy and video-based communication
What this could lead to
If it works, this could offer a simple, drug-free way to prevent delirium in stroke patients in the ICU, potentially improving recovery and reducing hospital stays.
What could go wrong
This is a very small early trial with only 34 participants, so results may not apply to all patients. The intervention is complex and may be hard to implement consistently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-85, * Patients scheduled for intensive care for at least 15 days due to SAH, unruptured intracranial aneurysm, and/or Arterovenous Malformation, * Those with a Mini Mental State Examination score of \> 24, * Those with a Glasgow Coma Score of 15, * Those with motor function in at least one extremity, * Those with pain \< 5/10 (according to the NRS) Exclusion Criteria: * Patients whose GCS fell to 14 or below for any reason during the study period; * Patients who developed septic shock and MODS; * Patients requiring endotrachial intubation and mechanical ventilation due to ARDS; * Those requiring vasopressors such as NE at a rate of \>0.25 mcg/kg/min; * Terminal cancer cases; * Patients with advanced chronic heart and lung failure and COPD; * Those with a METS (exercise capacity) of \<4; * Those with a history of dementia, Alzheimer's disease, or psychiatric illness; * Those with vision, hearing, or speech problems that would interfere with communication; * Those with a history of epilepsy;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arteriovenous malformation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arteriovenous hemangioma/malformation brain aneurysm Communication subarachnoid hemorrhage delirium prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Subarachnoid haemorrhagic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karadeniz Technical University, Farabi Hospital

    Trabzon, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.